Puromycin, 500 mg

An aminonucleoside antibiotic originally isolated from Streptomyces alboniger, puromycin from STEMCELL Technologies inhibits protein synthesis by mimicking aminoacyl-tRNA and triggering premature chain termination at the ribosomal A site. This 500 mg vial serves as a robust selection reagent across cell culture and microbiology workflows, enabling rapid isolation of mammalian cells, bacteria, and yeast that stably express the pac (puromycin N-acetyltransferase) resistance gene.

For mammalian cell selection, working concentrations typically range from 1 to 10 µg/mL, with the optimal dose depending on the cell line; bacterial cultures are generally selected on media containing 50 to 200 µg/mL. Researchers commonly apply the antibiotic 24 to 48 hours post-transfection, with stable populations usually established within 5 to 7 days of continuous selection. The compound integrates easily into standard CRISPR/Cas9 gene editing pipelines, lentiviral production protocols, and hybridoma generation workflows, and is frequently paired with fluorescent or drug-based co-selection markers during pooled screens.

This research-use-only reagent is supplied as a lyophilized powder in a single vial for reconstitution in sterile water or buffer. Store protected from light at -20 °C in a desiccated environment, and avoid repeated freeze-thaw cycles of working aliquots to preserve activity. Once reconstituted, stock solutions typically remain stable for several months when stored at -20 °C, supporting both small-scale transfections and larger selection campaigns.